Medical Necessity Evaluation Criteria

Required Information for Medical Necessity Determination

A confirmed diagnosis with pathologic or clinical confirmation is required to evaluate medical necessity, according to the American College of Physicians 1
Complete medical history, including comorbid conditions, is necessary to assess treatment selection, as recommended by the American Medical Association 1
Current medications and previous treatments must be assessed for drug interactions, as suggested by the American Pharmacists Association 1
Organ-specific function assessment, including baseline laboratory tests, is essential for treatment planning, according to the American College of Radiology 1
Documented allergies or hypersensitivity reactions with specific details on severity and timing are crucial for safe treatment, as emphasized by the American Academy of Allergy, Asthma, and Immunology 1

Medical necessity requires that treatment addresses a confirmed diagnosis with appropriate clinical evaluation, as stated by the American Medical Association 1
Treatment must be supported by evidence-based guidelines or accepted clinical standards, according to the American College of Physicians 2
Clearly defined therapeutic goals with measurable outcomes are necessary for effective treatment, as recommended by the American Academy of Child and Adolescent Psychiatry 3
Treatment should represent the least restrictive approach likely to achieve clinical success, as suggested by the American Thoracic Society 4

Treatment is considered standard of care when supported by high-quality evidence from randomized controlled trials or meta-analyses, according to the American Medical Association 2
Consensus expert opinion is considered when high-quality evidence is unavailable, as stated by the American College of Physicians 2
Recognition by specialty societies, such as the National Comprehensive Cancer Network (NCCN), is important for standard of care determination, as emphasized by the American Academy of Dermatology 5
Treatment should not be considered experimental or investigational by major guideline organizations, according to the American Academy of Dermatology 5

Most clinical practice guidelines are supported by suboptimal evidence, with fewer than 1 in 10 recommendations based on high-quality evidence, as noted by the American Medical Association 2
Guidelines should be cautiously applied and should not automatically be considered standard of care without examining the underlying evidence quality, as recommended by the American College of Physicians 2

The European Journal of Heart Failure suggests that guideline recommendations should not be confused with standard of care without examining the underlying evidence quality, and individual factors must be considered for each patient 6
The Annals of Oncology indicates that treatment is likely experimental or investigational when used outside of established indications without supporting evidence, and a distinction should be made between physiologically effective treatments and those that provide meaningful clinical benefit to the patient 7

The American Urological Association recommends that practitioners should persist with treatments for sufficient duration (4-8 weeks for medications, 8-12 weeks for other therapies) to determine efficacy before continuing, and therapies that do not demonstrate efficacy after an adequate trial should be ceased, with a methodical approach to combination or continuation of therapies 8, 9
The European Society for Medical Oncology suggests that treatment should represent the least restrictive approach likely to achieve clinical success while maximizing overall survival and quality of life while minimizing toxicity 10